Skip to main content

High risk of recurrent venous thromboembolism in BCR-ABL-negative myeloproliferative neoplasms after termination of anticoagulation

Abstract

Venous thromboembolism (VTE) is a major burden in patients with BCR-ABL-negative myeloproliferative neoplasms (MPN). In addition to cytoreductive treatment anticoagulation is mandatory, but optimal duration of anticoagulation is a matter of debate. In our single center study, we retrospectively included 526 MPN patients. In total, 78 of 526 MPN patients (14.8%) had 99 MPN-associated VTE. Median age at first VTE was 52.5 years (range 23–81). During a study period of 3497 years, a VTE event rate of 1.7% per patient/year was detected. 38.4% (38/99) of all VTEs appeared before or at MPN diagnosis and 55.6% (55/99) occurred at “uncommon” sites like splanchnic or cerebral veins. MPN patients with VTEs were significantly more female (p = 0.028), JAK2 positive (p = 0.018), or had a polycythemia vera (p = 0.009). MPN patients without VTEs were more often CALR positive (p = 0.023). Total study period after first VTE was 336 years with 20 VTE recurrences accounting for a recurrence rate of 6% per patient/year. In 36 of 71 MPN patients with anticoagulation therapy after first VTE event (50.7%), prophylactic anticoagulation was terminated after a median time of 6 months (range 1–61); 13 of those 36 patients (36.1%) had a VTE recurrence after a median of 13 months (range 4–168). In contrast, only three of 35 (8.6%) patients with ongoing anticoagulation had a VTE recurrence (p = 0.0127). Thus, termination of prophylactic anticoagulation was associated with a significantly higher risk of VTE recurrence. Our data suggest that in MPN patients with VTE, a prolonged duration of anticoagulation may be beneficial.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2

References

  1. Hultcrantz M, Wilkes SR, Kristinsson SY et al (2015) Risk and cause of death in patients diagnosed with myeloproliferative neoplasms in Sweden between 1973 and 2005: a population-based study. J Clin Oncol 33(20):2285–2295

    Article  Google Scholar 

  2. Kaifie A, Kirschner M, Wolf D et al (2016a) Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry. J Hematol Oncol 9:18

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Landolfi R, Marchiolo R, Kutti J et al (2004) Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 350:114–124

    Article  CAS  PubMed  Google Scholar 

  4. Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, Wilkins BS, van der Walt JD, Reilly JT, Grigg AP, Revell P, Woodcock BE, Green AR (2005) Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 353:33–45

    Article  CAS  PubMed  Google Scholar 

  5. Goldhaber SZ (2012) Venous thromboembolism: epidemiology and magnitude of the problem. Best Pract Res Clin Haematol 25(3):235–242

    Article  PubMed  Google Scholar 

  6. Sekhar M, McVinnie K, Burroughs AK (2013) Splanchnic vein thrombosis in myeloproliferative neoplasms. Br J Haematol 162(6):730–747

    Article  CAS  PubMed  Google Scholar 

  7. De Stefano V, Martinelli I (2010) Splanchnic vein thrombosis: clinical presentation, risk factors and treatment. Intern Emerg Med 5(6):487–494

    Article  PubMed  Google Scholar 

  8. Bertozzi I, Bogoni G, Biagetti G, Duner E, Lombardi AM, Fabris F, Randi ML (2017) Thromboses and hemorrhages are common in MPN patients with high JAK2V617F allel burden. Ann Hematol 96(8):1297–1302

    Article  CAS  PubMed  Google Scholar 

  9. Pei YQ, Wu Y, Wang F, Cui W (2016) Prognostic value of CALR vs. JAK2V617F mutations on splenomegaly, leukemic transformation, thrombosis, and overall survival in patients with primary fibrosis: a meta-analysis. Ann Hematol 95(9):1391–1398

    Article  CAS  PubMed  Google Scholar 

  10. De Stefano V, Ruggeri M, Cervantes F et al (2016a) High rate of recurrent venous thromboembolism in patients with myeloproliferative neoplasms and effect of prophylaxis with vitamin K antagonists. Leukemia 30(10):2032–2038

    Article  CAS  PubMed  Google Scholar 

  11. Bauersachs R, Berkowitz SD, Brenner B et al (2010) Oral Rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 363(26):2499–2510

    Article  CAS  Google Scholar 

  12. Buller HR, Prins MH, Lensin AW et al (2012) Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 366(14):1287–1297

    Article  PubMed  Google Scholar 

  13. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Masiukiewicz U, Pak R, Thompson J, Raskob GE, Weitz JI (2013) Oral Apixaban for the treatment of acute venous thromboembolism. N Engl J Med 369(9):799–808

    Article  CAS  Google Scholar 

  14. Buller HR, Decousus H, Grosso MA et al (2013) Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 369(15):1406–1415

    Article  CAS  PubMed  Google Scholar 

  15. Hernandez-Boluda JC, Arellano-Rodrigo E, Cervantes F et al (2015) Oral anticoagulation to prevent thrombosis recurrence in polycythemia vera and essential thrombocythemia. Ann Hematol 94(6):911–918

    Article  CAS  PubMed  Google Scholar 

  16. Ellis MH, Lavi N, Vannucchi A, Harrison C (2014) Treatment of thrombembolic events coincident with the diagnosis of myeloproliferative neoplasms: a physicians survey. Thromb Res 134:251–254

    Article  CAS  PubMed  Google Scholar 

  17. De Stefano V, Za T, Rossi E et al (2008) Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors and effect of treatments. Haematologica 93(3):372–380

    Article  CAS  PubMed  Google Scholar 

  18. Cushman M (2007) Epidemiology and risk factors for venous thrombosis. Semin Hematol 44(2):62–69

    Article  PubMed  PubMed Central  Google Scholar 

  19. Kreher S, Ochsenreither S, Trappe RU, Pabinger I, Bergmann F, Petrides PE, Koschmieder S, Matzdorff A, Tiede A, Griesshammer M, Riess H (2014) Prophylaxis and management of venous thromboembolism in patients with myeloproliferative neoplasm: consensus statement of DGHO, ÖGHO and GTH. Ann Hematol 93(12):1953–1963

    Article  CAS  PubMed  Google Scholar 

  20. Tefferi A, Barbui T (2017) Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification and management. Am J Hematol 92(1):94–108

    Article  CAS  PubMed  Google Scholar 

  21. Kaatz S, Ahmad D, Spyropoulos AC, Schulman S, the Subcommittee on Control of Anticoagulation (2015) Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. J Thromb Haemost 13:2119–2126

    Article  CAS  Google Scholar 

  22. Marchioli R, Finazzi G, Landolfi R, Kutti J, Gisslinger H, Patrono C, Marilus R, Villegas A, Tognoni G, Barbui T (2005) Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol 23(10):2224–2232

    Article  PubMed  Google Scholar 

  23. Marchioli R, Finazzi G, Specchia G, Cacciola R, Cavazzina R, Cilloni D, de Stefano V, Elli E, Iurlo A, Latagliata R, Lunghi F, Lunghi M, Marfisi RM, Musto P, Masciulli A, Musolino C, Cascavilla N, Quarta G, Randi ML, Rapezzi D, Ruggeri M, Rumi E, Scortechini AR, Santini S, Scarano M, Siragusa S, Spadea A, Tieghi A, Angelucci E, Visani G, Vannucchi AM, Barbui T (2013) Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med 368(1):22–33

    Article  CAS  PubMed  Google Scholar 

  24. Gissliner H, Gotic M, Holowiecki J et al (2013) Anagrelid compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. Blood 121(10):1720–1728

    Article  CAS  Google Scholar 

  25. Carobbio A, Thiele J, Passamonti F, Rumi E, Ruggeri M, Rodeghiero F, Randi ML, Bertozzi I, Vannucchi AM, Antonioli E, Gisslinger H, Buxhofer-Ausch V, Finazzi G, Gangat N, Tefferi A, Barbui T (2011) Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. Blood 117(22):5857–5859

    Article  CAS  PubMed  Google Scholar 

  26. Barbui T, Carobbio A, Cervantes F, Vannucchi AM, Guglielmelli P, Antonioli E, Alvarez-Larran A, Rambaldi A, Finazzi G, Barosi G (2010) Thrombosis in primary myelofibrosis: incidence and risk factors. Blood 115(4):778–782

    Article  CAS  PubMed  Google Scholar 

  27. Kaifie A, Kirschner M, Wolf D et al (2016) Bleeding, thrombosis, and anticoagulation in myeloproloferative neoplasms (MPN): analysis from the German SAL-MPN-registry. J Hematol Oncol 9:18

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Cervantes F, Alvarez-Larran A, Arellano-Rodrigo E et al (2006) Frequency and risk factors for thrombosis in idiopathic myelofibrosis: analysis in a serie of 155 patients from a single institution. Leukemia 20(1):55–60

    Article  CAS  PubMed  Google Scholar 

  29. De Stefano V, Vannucchi AM, Ruggeri M et al (2016b) Splanchnic vein thrombosis in myeloproliferative neoplasms: risk factors for recurrences in a cohort of 181 patients. Blood Cancer J 6(11):e493

    Article  PubMed  PubMed Central  Google Scholar 

  30. Haider M, Gangat N, Lasho T, Abou Hussein AK, Elala YC, Hanson C, Tefferi A (2016) Validation of the revised international prognostic score of thrombosis for essential thrombocythemia (IPSET-thrombosis) in 585 Mayo Clinic patients. Am J Hematol 91:390–394

    Article  PubMed  Google Scholar 

  31. Kearon C, Ginsberg JS, Anderson DR et al (2003) Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thrombembolism. N Engl J Med 349(7):631–639

    Article  CAS  PubMed  Google Scholar 

  32. Lussana F, Caberlon S, Pagani C, Kamphuisen PW, Büller HR, Cattaneo M (2009) Association of V617F JAK2 mutation with the risk of thrombosis among patients with essential thrombocythemia or idiopathic myelofibrosis: a systematic review. Thromb Res 124(4):409–417

    Article  CAS  PubMed  Google Scholar 

  33. Finazzi MC, Carobbio A, Cervantes F, Isola IM, Vannucchi AM, Guglielmelli P, Rambaldi A, Finazzi G, Barosi G, Barbui T (2015) CALR mutation, MPL mutation and triple negativitiy identify patients with lowest vascular risk in primary myelofibrosis. Leukemia 29(5):1209–1210

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Kai Wille.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wille, K., Sadjadian, P., Becker, T. et al. High risk of recurrent venous thromboembolism in BCR-ABL-negative myeloproliferative neoplasms after termination of anticoagulation. Ann Hematol 98, 93–100 (2019). https://doi.org/10.1007/s00277-018-3483-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-018-3483-6

Keywords